The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Drugs for the treatment of primary immunodeficiency diseases
Highlights
The global Primary Immunodeficiency Drugs market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
The major global manufacturers of Primary Immunodeficiency Drugs include ADMA Biologics, Inc., CSL Behring, LLC, Octapharma, Takeda Pharmaceutical Company, Grifols Biologicals, Inc., Baxter, Kedrion Biopharma, BPL Inc. and Pharming Group, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Cytokines, which accounted for % of the global market of Primary Immunodeficiency Drugs in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Primary Immunodeficiency Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Immunodeficiency Drugs.
The Primary Immunodeficiency Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Primary Immunodeficiency Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Immunodeficiency Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Some of the prominent players reviewed in the research report include:
- ADMA Biologics, Inc.
- CSL Behring, LLC
- Octapharma
- Takeda Pharmaceutical Company
- Grifols Biologicals, Inc.
- Baxter
- Kedrion Biopharma
- BPL Inc.
- Pharming Group
- Shire
- Chengdu Rongsheng Pharmaceutical Co., Ltd
Product Type Insights
Global markets are presented by Primary Immunodeficiency Drugs type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Primary Immunodeficiency Drugs are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Primary Immunodeficiency Drugs segment by Type
- Cytokines
- Anti Cytokine Antibodies
- Signal Molecule Inhibitor
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Primary Immunodeficiency Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Primary Immunodeficiency Drugs market.
Primary Immunodeficiency Drugs segment by Application
- Hospital
- Specialist Clinic
- Othere
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Russia)
- Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
- Latin America (Mexico, Brazil, Argentina, Colombia)
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Primary Immunodeficiency Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
- This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Immunodeficiency Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
- This report will help stakeholders to understand the global industry status and trends of Primary Immunodeficiency Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
- This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
- This report stays updated with novel technology integration, features, and the latest developments in the market
- This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Primary Immunodeficiency Drugs industry.
- This report helps stakeholders to gain insights into which regions to target globally
- This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Immunodeficiency Drugs.
- This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Primary Immunodeficiency Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Primary Immunodeficiency Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
Index
1 Primary Immunodeficiency Drugs Market Overview
1.1 Product Overview and Scope of Primary Immunodeficiency Drugs
1.2 Primary Immunodeficiency Drugs Segment by Type
1.2.1 Global Primary Immunodeficiency Drugs Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Cytokines
1.2.3 Anti Cytokine Antibodies
1.2.4 Signal Molecule Inhibitor
1.3 Primary Immunodeficiency Drugs Segment by Application
1.3.1 Global Primary Immunodeficiency Drugs Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Specialist Clinic
1.3.4 Othere
1.4 Global Primary Immunodeficiency Drugs Market Size Estimates and Forecasts
1.4.1 Global Primary Immunodeficiency Drugs Revenue 2017-2028
1.4.2 Global Primary Immunodeficiency Drugs Sales 2017-2028
1.4.3 Primary Immunodeficiency Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Primary Immunodeficiency Drugs Market Competition by Manufacturers
2.1 Global Primary Immunodeficiency Drugs Sales Market Share by Manufacturers (2017-2022)
2.2 Global Primary Immunodeficiency Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Primary Immunodeficiency Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Primary Immunodeficiency Drugs Manufacturing Sites, Area Served, Product Type
2.5 Primary Immunodeficiency Drugs Market Competitive Situation and Trends
2.5.1 Primary Immunodeficiency Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Primary Immunodeficiency Drugs Players Market Share by Revenue
2.5.3 Global Primary Immunodeficiency Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Primary Immunodeficiency Drugs Retrospective Market Scenario by Region
3.1 Global Primary Immunodeficiency Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Primary Immunodeficiency Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Primary Immunodeficiency Drugs Market Facts & Figures by Country
3.3.1 North America Primary Immunodeficiency Drugs Sales by Country
3.3.2 North America Primary Immunodeficiency Drugs Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Primary Immunodeficiency Drugs Market Facts & Figures by Country
3.4.1 Europe Primary Immunodeficiency Drugs Sales by Country
3.4.2 Europe Primary Immunodeficiency Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Primary Immunodeficiency Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Primary Immunodeficiency Drugs Sales by Region
3.5.2 Asia Pacific Primary Immunodeficiency Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Primary Immunodeficiency Drugs Market Facts & Figures by Country
3.6.1 Latin America Primary Immunodeficiency Drugs Sales by Country
3.6.2 Latin America Primary Immunodeficiency Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Primary Immunodeficiency Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Primary Immunodeficiency Drugs Sales by Country
3.7.2 Middle East and Africa Primary Immunodeficiency Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Primary Immunodeficiency Drugs Historic Market Analysis by Type
4.1 Global Primary Immunodeficiency Drugs Sales Market Share by Type (2017-2022)
4.2 Global Primary Immunodeficiency Drugs Revenue Market Share by Type (2017-2022)
4.3 Global Primary Immunodeficiency Drugs Price by Type (2017-2022)
5 Global Primary Immunodeficiency Drugs Historic Market Analysis by Application
5.1 Global Primary Immunodeficiency Drugs Sales Market Share by Application (2017-2022)
5.2 Global Primary Immunodeficiency Drugs Revenue Market Share by Application (2017-2022)
5.3 Global Primary Immunodeficiency Drugs Price by Application (2017-2022)
6 Key Companies Profiled
6.1 ADMA Biologics, Inc.
6.1.1 ADMA Biologics, Inc. Corporation Information
6.1.2 ADMA Biologics, Inc. Description and Business Overview
6.1.3 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Sales, Revenue and Gross Margin (2017-2022)
6.1.4 ADMA Biologics, Inc. Primary Immunodeficiency Drugs Product Portfolio
6.1.5 ADMA Biologics, Inc. Recent Developments/Updates
6.2 CSL Behring, LLC
6.2.1 CSL Behring, LLC Corporation Information
6.2.2 CSL Behring, LLC Description and Business Overview
6.2.3 CSL Behring, LLC Primary Immunodeficiency Drugs Sales, Revenue and Gross Margin (2017-2022)
6.2.4 CSL Behring, LLC Primary Immunodeficiency Drugs Product Portfolio
6.2.5 CSL Behring, LLC Recent Developments/Updates
6.3 Octapharma
6.3.1 Octapharma Corporation Information
6.3.2 Octapharma Description and Business Overview
6.3.3 Octapharma Primary Immunodeficiency Drugs Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Octapharma Primary Immunodeficiency Drugs Product Portfolio
6.3.5 Octapharma Recent Developments/Updates
6.4 Takeda Pharmaceutical Company
6.4.1 Takeda Pharmaceutical Company Corporation Information
6.4.2 Takeda Pharmaceutical Company Description and Business Overview
6.4.3 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Product Portfolio
6.4.5 Takeda Pharmaceutical Company Recent Developments/Updates
6.5 Grifols Biologicals, Inc.
6.5.1 Grifols Biologicals, Inc. Corporation Information
6.5.2 Grifols Biologicals, Inc. Description and Business Overview
6.5.3 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Product Portfolio
6.5.5 Grifols Biologicals, Inc. Recent Developments/Updates
6.6 Baxter
6.6.1 Baxter Corporation Information
6.6.2 Baxter Description and Business Overview
6.6.3 Baxter Primary Immunodeficiency Drugs Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Baxter Primary Immunodeficiency Drugs Product Portfolio
6.6.5 Baxter Recent Developments/Updates
6.7 Kedrion Biopharma
6.6.1 Kedrion Biopharma Corporation Information
6.6.2 Kedrion Biopharma Description and Business Overview
6.6.3 Kedrion Biopharma Primary Immunodeficiency Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Kedrion Biopharma Primary Immunodeficiency Drugs Product Portfolio
6.7.5 Kedrion Biopharma Recent Developments/Updates
6.8 BPL Inc.
6.8.1 BPL Inc. Corporation Information
6.8.2 BPL Inc. Description and Business Overview
6.8.3 BPL Inc. Primary Immunodeficiency Drugs Sales, Revenue and Gross Margin (2017-2022)
6.8.4 BPL Inc. Primary Immunodeficiency Drugs Product Portfolio
6.8.5 BPL Inc. Recent Developments/Updates
6.9 Pharming Group
6.9.1 Pharming Group Corporation Information
6.9.2 Pharming Group Description and Business Overview
6.9.3 Pharming Group Primary Immunodeficiency Drugs Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Pharming Group Primary Immunodeficiency Drugs Product Portfolio
6.9.5 Pharming Group Recent Developments/Updates
6.10 Shire
6.10.1 Shire Corporation Information
6.10.2 Shire Description and Business Overview
6.10.3 Shire Primary Immunodeficiency Drugs Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Shire Primary Immunodeficiency Drugs Product Portfolio
6.10.5 Shire Recent Developments/Updates
6.11 Chengdu Rongsheng Pharmaceutical Co., Ltd
6.11.1 Chengdu Rongsheng Pharmaceutical Co., Ltd Corporation Information
6.11.2 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Description and Business Overview
6.11.3 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Product Portfolio
6.11.5 Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Developments/Updates
7 Primary Immunodeficiency Drugs Manufacturing Cost Analysis
7.1 Primary Immunodeficiency Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Primary Immunodeficiency Drugs
7.4 Primary Immunodeficiency Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Primary Immunodeficiency Drugs Distributors List
8.3 Primary Immunodeficiency Drugs Customers
9 Primary Immunodeficiency Drugs Market Dynamics
9.1 Primary Immunodeficiency Drugs Industry Trends
9.2 Primary Immunodeficiency Drugs Market Drivers
9.3 Primary Immunodeficiency Drugs Market Challenges
9.4 Primary Immunodeficiency Drugs Market Restraints
10 Global Market Forecast
10.1 Primary Immunodeficiency Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Primary Immunodeficiency Drugs by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Primary Immunodeficiency Drugs by Type (2023-2028)
10.2 Primary Immunodeficiency Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Primary Immunodeficiency Drugs by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Primary Immunodeficiency Drugs by Application (2023-2028)
10.3 Primary Immunodeficiency Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Primary Immunodeficiency Drugs by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Primary Immunodeficiency Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
List of Tables
Table 1. Global Primary Immunodeficiency Drugs Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Primary Immunodeficiency Drugs Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Primary Immunodeficiency Drugs Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Primary Immunodeficiency Drugs Market Competitive Situation by Manufacturers in 2021
Table 5. Global Primary Immunodeficiency Drugs Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Primary Immunodeficiency Drugs Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Primary Immunodeficiency Drugs Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Primary Immunodeficiency Drugs Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Primary Immunodeficiency Drugs Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Primary Immunodeficiency Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Primary Immunodeficiency Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Primary Immunodeficiency Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Immunodeficiency Drugs as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Primary Immunodeficiency Drugs Sales by Region (2017-2022) & (K Units)
Table 16. Global Primary Immunodeficiency Drugs Sales Market Share by Region (2017-2022)
Table 17. Global Primary Immunodeficiency Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Primary Immunodeficiency Drugs Revenue Market Share by Region (2017-2022)
Table 19. North America Primary Immunodeficiency Drugs Sales by Country (2017-2022) & (K Units)
Table 20. North America Primary Immunodeficiency Drugs Sales Market Share by Country (2017-2022)
Table 21. North America Primary Immunodeficiency Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Primary Immunodeficiency Drugs Revenue Market Share by Country (2017-2022)
Table 23. Europe Primary Immunodeficiency Drugs Sales by Country (2017-2022) & (K Units)
Table 24. Europe Primary Immunodeficiency Drugs Sales Market Share by Country (2017-2022)
Table 25. Europe Primary Immunodeficiency Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Primary Immunodeficiency Drugs Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Primary Immunodeficiency Drugs Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Primary Immunodeficiency Drugs Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Primary Immunodeficiency Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Primary Immunodeficiency Drugs Revenue Market Share by Region (2017-2022)
Table 31. Latin America Primary Immunodeficiency Drugs Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Primary Immunodeficiency Drugs Sales Market Share by Country (2017-2022)
Table 33. Latin America Primary Immunodeficiency Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Primary Immunodeficiency Drugs Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Primary Immunodeficiency Drugs Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Primary Immunodeficiency Drugs Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Primary Immunodeficiency Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Primary Immunodeficiency Drugs Revenue Market Share by Country (2017-2022)
Table 39. Global Primary Immunodeficiency Drugs Sales by Type (2017-2022) & (K Units)
Table 40. Global Primary Immunodeficiency Drugs Sales Market Share by Type (2017-2022)
Table 41. Global Primary Immunodeficiency Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Primary Immunodeficiency Drugs Revenue Share by Type (2017-2022)
Table 43. Global Primary Immunodeficiency Drugs Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Primary Immunodeficiency Drugs Sales (K Units) by Application (2017-2022)
Table 45. Global Primary Immunodeficiency Drugs Sales Market Share by Application (2017-2022)
Table 46. Global Primary Immunodeficiency Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Primary Immunodeficiency Drugs Revenue Share by Application (2017-2022)
Table 48. Global Primary Immunodeficiency Drugs Price by Application (2017-2022) & (US$/Unit)
Table 49. ADMA Biologics, Inc. Corporation Information
Table 50. ADMA Biologics, Inc. Description and Business Overview
Table 51. ADMA Biologics, Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. ADMA Biologics, Inc. Primary Immunodeficiency Drugs Product
Table 53. ADMA Biologics, Inc. Recent Developments/Updates
Table 54. CSL Behring, LLC Corporation Information
Table 55. CSL Behring, LLC Description and Business Overview
Table 56. CSL Behring, LLC Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. CSL Behring, LLC Primary Immunodeficiency Drugs Product
Table 58. CSL Behring, LLC Recent Developments/Updates
Table 59. Octapharma Corporation Information
Table 60. Octapharma Description and Business Overview
Table 61. Octapharma Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Octapharma Primary Immunodeficiency Drugs Product
Table 63. Octapharma Recent Developments/Updates
Table 64. Takeda Pharmaceutical Company Corporation Information
Table 65. Takeda Pharmaceutical Company Description and Business Overview
Table 66. Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Takeda Pharmaceutical Company Primary Immunodeficiency Drugs Product
Table 68. Takeda Pharmaceutical Company Recent Developments/Updates
Table 69. Grifols Biologicals, Inc. Corporation Information
Table 70. Grifols Biologicals, Inc. Description and Business Overview
Table 71. Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Grifols Biologicals, Inc. Primary Immunodeficiency Drugs Product
Table 73. Grifols Biologicals, Inc. Recent Developments/Updates
Table 74. Baxter Corporation Information
Table 75. Baxter Description and Business Overview
Table 76. Baxter Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Baxter Primary Immunodeficiency Drugs Product
Table 78. Baxter Recent Developments/Updates
Table 79. Kedrion Biopharma Corporation Information
Table 80. Kedrion Biopharma Description and Business Overview
Table 81. Kedrion Biopharma Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Kedrion Biopharma Primary Immunodeficiency Drugs Product
Table 83. Kedrion Biopharma Recent Developments/Updates
Table 84. BPL Inc. Corporation Information
Table 85. BPL Inc. Description and Business Overview
Table 86. BPL Inc. Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. BPL Inc. Primary Immunodeficiency Drugs Product
Table 88. BPL Inc. Recent Developments/Updates
Table 89. Pharming Group Corporation Information
Table 90. Pharming Group Description and Business Overview
Table 91. Pharming Group Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Pharming Group Primary Immunodeficiency Drugs Product
Table 93. Pharming Group Recent Developments/Updates
Table 94. Shire Corporation Information
Table 95. Shire Description and Business Overview
Table 96. Shire Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Shire Primary Immunodeficiency Drugs Product
Table 98. Shire Recent Developments/Updates
Table 99. Chengdu Rongsheng Pharmaceutical Co., Ltd Corporation Information
Table 100. Chengdu Rongsheng Pharmaceutical Co., Ltd Description and Business Overview
Table 101. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 102. Chengdu Rongsheng Pharmaceutical Co., Ltd Primary Immunodeficiency Drugs Product
Table 103. Chengdu Rongsheng Pharmaceutical Co., Ltd Recent Developments/Updates
Table 104. Production Base and Market Concentration Rate of Raw Material
Table 105. Key Suppliers of Raw Materials
Table 106. Primary Immunodeficiency Drugs Distributors List
Table 107. Primary Immunodeficiency Drugs Customers List
Table 108. Primary Immunodeficiency Drugs Market Trends
Table 109. Primary Immunodeficiency Drugs Market Drivers
Table 110. Primary Immunodeficiency Drugs Market Challenges
Table 111. Primary Immunodeficiency Drugs Market Restraints
Table 112. Global Primary Immunodeficiency Drugs Sales Forecast by Type (2023-2028) & (K Units)
Table 113. Global Primary Immunodeficiency Drugs Sales Market Share Forecast by Type (2023-2028)
Table 114. Global Primary Immunodeficiency Drugs Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 115. Global Primary Immunodeficiency Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 116. Global Primary Immunodeficiency Drugs Sales Forecast by Application (2023-2028) & (K Units)
Table 117. Global Primary Immunodeficiency Drugs Sales Market Share Forecast by Application (2023-2028)
Table 118. Global Primary Immunodeficiency Drugs Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 119. Global Primary Immunodeficiency Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 120. Global Primary Immunodeficiency Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 121. Global Primary Immunodeficiency Drugs Sales Market Share Forecast by Region (2023-2028)
Table 122. Global Primary Immunodeficiency Drugs Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 123. Global Primary Immunodeficiency Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Primary Immunodeficiency Drugs
Figure 2. Global Primary Immunodeficiency Drugs Market Share by Type in 2021 & 2028
Figure 3. Cytokines Product Picture
Figure 4. Anti Cytokine Antibodies Product Picture
Figure 5. Signal Molecule Inhibitor Product Picture
Figure 6. Global Primary Immunodeficiency Drugs Market Share by Application in 2021 & 2028
Figure 7. Hospital
Figure 8. Specialist Clinic
Figure 9. Othere
Figure 10. Global Primary Immunodeficiency Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Primary Immunodeficiency Drugs Market Size (2017-2028) & (US$ Million)
Figure 12. Global Primary Immunodeficiency Drugs Sales (2017-2028) & (K Units)
Figure 13. Primary Immunodeficiency Drugs Sales Share by Manufacturers in 2021
Figure 14. Global Primary Immunodeficiency Drugs Revenue Share by Manufacturers in 2021
Figure 15. The Global 5 and 10 Largest Primary Immunodeficiency Drugs Players: Market Share by Revenue in 2021
Figure 16. Primary Immunodeficiency Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 17. Global Primary Immunodeficiency Drugs Sales Market Share by Region (2017-2022)
Figure 18. Global Primary Immunodeficiency Drugs Sales Market Share by Region in 2021
Figure 19. Global Primary Immunodeficiency Drugs Revenue Market Share by Region (2017-2022)
Figure 20. Global Primary Immunodeficiency Drugs Revenue Market Share by Region in 2021
Figure 21. United States Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Canada Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Germany Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. France Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. U.K. Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Italy Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Russia Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. China Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Japan Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. South Korea Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. India Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Australia Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. China Taiwan Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Indonesia Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Thailand Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Malaysia Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Mexico Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Brazil Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Argentina Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Colombia Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Turkey Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Saudi Arabia Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. UAE Primary Immunodeficiency Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Sales Market Share of Primary Immunodeficiency Drugs by Type (2017-2022)
Figure 45. Manufacturing Cost Structure of Primary Immunodeficiency Drugs
Figure 46. Manufacturing Process Analysis of Primary Immunodeficiency Drugs
Figure 47. Primary Immunodeficiency Drugs Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
